Feature | May 14, 2014

Health care providers invited to review and comment on recommendations before final publication

May 14, 2014 — The National Lipid Assn. (NLA) released a draft summary that highlights key aspects of care that provide a thorough supplement and direction for clinicians treating patients with dyslipidemia.


The document was created by an expert panel comprised of NLA members who are leaders in the field of clinical lipidology. The panel’s goal was to harmonize guidelines among what has been presented in the past by the ATP panel, the American Heart Assn./American College of Cardiology and those also released in the international community.


“We wanted to make sure that any clinician following guidelines realizes that they are just that: guidelines to be used in a broad sense of the word,” said Matthew K. Ito, doctor of pharmacy and president of the NLA. “But we realize that individual patients bring a set of problems that are relatively uncommon when considered as a package. Considering only risk factors that are suitable to community-based analysis does not get the job done. Generalizations based on such data can often lead to an unsatisfactory approach to the individual patient.”


As such, the NLA recommendations make it clear that clinicians should assess patient risk and be able then to identify a treatment regime that gets the patient to well established goals.


“As lipidologists, the NLA wants to assist all clinicians to best manage their patients within the context of 'real world' medicine,” said Ito. “We believe these recommendations do that; they are both clinically practical and scientifically based.”


While the NLA encourages adoption and use of these recommendations, it recognizes that clinical judgment and evolving evidence constantly need to be incorporated to fortify clinician approaches to patient care.


Highlights of the recommendations for patient-centered treatment of dyslipidemia include:


Assessing Risk


Risk identification is the first crucial step to arrive at appropriate decisions by the health care provider and the patient to initiate healthy lifestyle changes and, potentially, drug therapy. The highest risk patients for future cardiovascular disease (CVD) events will always be those with established atherosclerotic cardiovascular disease (ASCVD).
In primary prevention situations, the presence of three or more major risk factors, familial hypercholesterolemia (FH) and simultaneously occurring high-risk disease states (such as diabetes and chronic kidney disease) are to be considered high-risk status.
Risk calculators can be confusing for many clinicians but can be beneficial when addressing patients that fall in the moderate risk group. The Framingham Risk Score 10-year hard coronary heart disease (CHD) endpoints is the preferred one for clinical decisions. Lifetime risk can also be used for patients under 50 years old.

Measures and Goals


Non-HDL-C and LDL-C are the clinical measures of atherogenic lipoprotein contribution to ASCVD risk, and these parameters should be obtained in the baseline assessment and as targets of treatment.
Clinicians should always steer therapy toward meeting goals, including lifestyle choices like diet and exercise, and include therapeutics when necessary to achieve the stated goals.

The NLA is seeking input and comments from NLA members, stakeholder organizations and other related medical societies as well any other individual or group who cares for patients with dyslipidemias and other related disorders.


Comments on this document can be made until May 31, 2014 at www.lipid.org/publiccomments.


After the NLA has received comments from all entities, the expert panel will reconvene and consider every comment submitted regarding these recommendations. The expert panel will then review and adjudicates the comments, publishing a final paper in the September/October issue of the Journal of Clinical Lipidology.


For more information: www.lipid.org


Related Content

The Medicines Company, bivalirudin, Angiomax, litigation, Hospira Inc.
News | Cath Lab| July 22, 2015
The Medicines Company announced the U.S. Court of Appeals for the Federal Circuit Court has ruled against the company...
Xarelto, anticoagulant protocol, discharge, outcomes, DVT, PE
News | Antiplatelet and Anticoagulation Therapies| July 21, 2015
Two companion papers published in Academic Emergency Medicine  address the question of when it is appropriate to...
platelet-like particles, PLPs, clotting, substitute, Carver, Lyon, NIBIB

Cartoon representation of a deformable platelet-like particle with fibrin nanobodies attached

Feature | Antiplatelet and Anticoagulation Therapies| July 13, 2015
Researchers have created tiny gel particles that can perform the same essential functions as platelets. The particles...
idarucizumab, dabigatran, anticoagulant, Boehringer Ingelheim, RE-VERSE AD
News | Antiplatelet and Anticoagulation Therapies| July 07, 2015
Results from an interim analysis of the Phase III RE-VERSE AD patient study demonstrate that 5 g of idarucizumab...
ACC, Statin Intolerance App, statin therapy, muscle symptoms, pain
Technology | July 01, 2015
The American College of Cardiology (ACC) Statin Intolerance App is now available to help guide clinicians through the...
cangrelor, Kangreal, FDA approval, The Medicines Company, antiplatelet agent
Technology | June 22, 2015
The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug Administration (FDA) as...
VHA, dabigatran, patient adherence, JAMA, Mintu Turakhia
News | Antiplatelet and Anticoagulation Therapies| June 18, 2015
Atrial fibrillation patients on the anticoagulant dabigatran were more likely to adhere to the medication with...
Merck, IMPROVE-IT, results, New England Journal of Medicine, NEJM, Vytorin
News | Pharmaceuticals| June 17, 2015
Merck announced that the New England Journal of Medicine published the results of the IMPROVE-IT trial, an...
Brilinta, Ticagrelor, PEGASUS TIMI-54, ACC, results
Feature | Antiplatelet and Anticoagulation Therapies| June 10, 2015
AstraZeneca announced full results from the PEGASUS-TIMI 54 study, a large-scale outcomes trial investigating Brilinta...
News | June 04, 2015
Researchers from the University of Chicago and Stanford University combed through scientific literature on the...
Overlay Init